Antonio Millan-Jimenez
Overview
Explore the profile of Antonio Millan-Jimenez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
51
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia-Martinez de Bartolome R, Barrio-Torres J, Sebastian-Viana T, Vila-Miravet V, La Orden-Izquierdo E, Fernandez-Fernandez S, et al.
J Pediatr Gastroenterol Nutr
. 2024 Dec;
80(2):308-317.
PMID: 39663749
Objectives: To study the health-related quality of life (HRQoL) and its possible determinant factors in Spanish children with eosinophilic esophagitis (EoE) and their parents. Methods: Multicenter observational cross-sectional study. The...
2.
Millan-Jimenez A, Fernandez-Fontan I, Sobrino-Toro M, Fernandez-Torres B
An Pediatr (Engl Ed)
. 2023 Sep;
99(4):240-251.
PMID: 37770287
Introduction: The consumption of nutritional and protein supplements by adolescents may have important consequences for their health. Methods: Prospective observational study based on a survey of adolescents enrolled in 6...
3.
Millan-Jimenez A, Herrera-Limones R, Lopez-Escamilla A, Lopez-Rubio E, Torres-Garcia M
Int J Environ Res Public Health
. 2021 Jun;
18(11).
PMID: 34071078
The COVID-19 pandemic forced the population worldwide into lockdown. The purpose of this study was to assess the impact of this measure on the health and comfort of university students...
4.
Salvador-Martin S, Kaczmarczyk B, Alvarez R, Navas-Lopez V, Gallego-Fernandez C, Moreno-Alvarez A, et al.
Pharmaceutics
. 2021 Jan;
13(1).
PMID: 33429950
Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic...
5.
Herrera-Limones R, Millan-Jimenez A, Lopez-Escamilla A, Torres-Garcia M
Int J Environ Res Public Health
. 2020 Aug;
17(16).
PMID: 32824112
Medicine and architecture are disciplines with the main objectives of satisfying the fundamental needs of human beings: health, comfort, well-being, safety, and ensuring an acceptable quality of life in a...
6.
Salvador-Martin S, Bossacoma F, Pujol-Muncunill G, Navas-Lopez V, Gallego-Fernandez C, Viada J, et al.
J Pediatr Gastroenterol Nutr
. 2020 Aug;
71(4):508-515.
PMID: 32773718
Objectives: Inflammatory bowel disease (IBD) is more complex in children and they will have to live with the disease for much longer. For this reason, it is necessary to optimize...
7.
Salvador-Martin S, Pujol-Muncunill G, Bossacoma F, Navas-Lopez V, Gallego-Fernandez C, Segarra O, et al.
Br J Clin Pharmacol
. 2020 Jun;
87(2):447-457.
PMID: 32478906
Aims: Identifying DNA variants associated with trough serum anti-tumour necrosis factor (TNF) levels could predict response to treatment in inflammatory bowel disease (IBD). To date, no specific studies have been...
8.
Salvador-Martin S, Raposo-Gutierrez I, Navas-Lopez V, Gallego-Fernandez C, Moreno-Alvarez A, Solar-Boga A, et al.
Int J Mol Sci
. 2020 May;
21(9).
PMID: 32397546
Around a 20-30% of inflammatory bowel disease (IBD) patients are diagnosed before they are 18 years old. Anti-TNF drugs can induce and maintain remission in IBD, however, up to 30%...